$60,000 of GENMAB US INC. lobbying was just disclosed, from Q3 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Guidance on legislation and regulations regarding the creation and development of differentiated antibody therapeutics."
You can find more data on corporate lobbying on Quiver Quantitative.
GMAB Hedge Fund Activity
We have seen 113 institutional investors add shares of GMAB stock to their portfolio, and 114 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ALLIANCEBERNSTEIN L.P. removed 4,062,783 shares (-27.6%) from their portfolio in Q2 2025, for an estimated $83,937,096
- ORBIS ALLAN GRAY LTD added 2,209,659 shares (+38.7%) to their portfolio in Q2 2025, for an estimated $45,651,554
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 2,084,966 shares (+152.3%) to their portfolio in Q2 2025, for an estimated $43,075,397
- CUBIST SYSTEMATIC STRATEGIES, LLC removed 873,597 shares (-69.4%) from their portfolio in Q2 2025, for an estimated $18,048,514
- CITADEL ADVISORS LLC removed 857,470 shares (-19.4%) from their portfolio in Q2 2025, for an estimated $17,715,330
- AVIDITY PARTNERS MANAGEMENT LP added 650,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $13,429,000
- DDD PARTNERS, LLC removed 601,050 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $12,417,693
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
GMAB Analyst Ratings
Wall Street analysts have issued reports on $GMAB in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 10/02/2025
- Guggenheim issued a "Buy" rating on 09/24/2025
To track analyst ratings and price targets for GMAB, check out Quiver Quantitative's $GMAB forecast page.
GMAB Price Targets
Multiple analysts have issued price targets for $GMAB recently. We have seen 4 analysts offer price targets for $GMAB in the last 6 months, with a median target of $43.0.
Here are some recent targets:
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $40.0 on 10/15/2025
- Michael Schmitz from Guggenheim set a target price of $43.0 on 09/24/2025
- Asthika Goonewardene from Truist Securities set a target price of $46.0 on 07/08/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
